This highly conserved protein is largely overlooked by researchers but is at the core of immune functions, helping regulate ...
MA’s ZEPHYR Phase 2 trial in schizophrenia Last patient visit completed for ML-004’s IRIS Phase 2 trial in autism spectrum disorderTopline results from both Phase 2 trials expected by mid-August 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results